Second national study AML-BFM 98 improved remission rate and overall survival in children with acute myeloid leukemia in the Czech Republic

Czech version

Authors: J. Starý ¹; V. Vávra ¹; P. Gajdoš ¹; H. Hrstková ²; L. Kopečná ²; J. Štěrba ³; D. Dembická ³; D. Mendelová ³; V. Mihál ⁴; D. Pospíšilová ⁴; Z. Novák ⁴; B. Blažek ⁵; H. Ptoszková ⁵; J. Hak ⁶; K. Toušovská ⁶; D. Procházková ⁷; Z. Černá ⁸; Y. Jabali ⁹; P. Timr ⁹; P. Smíšek ¹; K. Zdráhalová ¹; P. Sedláček ¹; L. Šrámková ¹; P. Keslová ¹; R. Formánková ¹; V. Komrska ¹; E. Mejstříková ¹; A. Vrzalová ¹; K. Kramarzová ¹; K. Michalová ¹⁰; Z. Zemanová ¹⁰; M. Jarošová ¹¹; J. Housková ¹²; A. Zámková ¹²; J. Zuna ¹; O. Hrušák ¹; J. Trka ¹; J. Schwarz ¹³; U. Creutzig ¹⁴
Authors‘ workplace: Klinika dětské hematologie a onkologie UK 2. LF a FN Motol, Praha, 2I. dětská interní klinika LF MU a FN Brno, 3Klinika dětské onkologie FN Brno, 4Dětská klinika LF UP a FN Olomouc, 5Klinika dětského lékařství FN Ostrava, 6Dětská klinika FN Hradec Králové ¹; Centrum nádorové cytogenetiky, Ústav klinické biochemie a laboratorní diagnostiky, VFN a 1. LF UK, Praha, 11Hemato-onkologická klinika LF UP a FN Olomouc, 12Oddělení klinické hematologie FN Motol ¹⁰; Ústav hematologie a krevní transfuze, Praha, 14Universitätskinderklinik, Päd. Hematologie/Onkologie Münster, Německo ¹³
Published in: Transfuze Hematol. dnes,14, 2008, No. 4, p. 166-174.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Between 1998 and 2004 the Czech Republic participated with Germany, Austria and Switzerland in the international AML-BFM 98 study on the treatment of children with acute myeloid leukemia (AML). Both standard risk and high risk patients received 5 blocks of intensive chemotherapy including 2 blocks of high-dose cytosine arabinoside, prophylactic cranial irradiation and maintenance treatment lasting for one year. Randomized phase of treatment compared the classical consolidation of BFM protocols lasting for 6-weeks with two short blocks and assessed the role of G-CSF in the early phases of therapy. Treatment results were evaluated in 70 children divided into the standard risk (n = 34) and high risk (n = 36) groups according to the leukemia phenotype, genotype and early treatment response. Six children (9%) had Down syndrome. Remission was achieved in 60 children (85.7%) representing 12% improvement in comparison with the previous AML-BFM 93 study. Five children (7%) underwent either allogeneic (n = 4) or autologous (n = 1) bone marrow transplantation in the first remission. Nine children (15%) died in remission and 18 children (30%) suffered from relapse. Two children developed secondary leukemia (sMDS and sALL); both were rescued by unrelated bone marrow transplantation. Five-year EFS/OS was 44.3/57.1% for the whole group of patients with a median follow-up 6.9 years (4.1-9.3 y). EFS/OS in standard risk patients was 52.9/70.6%, in high risk 36.1/44.4%. The previous AML-BFM 93 study achieved 5-year EFS/OS 42.6/45.9% in the Czech Republic. Altogether, 473 patients were enrolled in the international AML-BFM 98 study and 88% of them achieved complete remission with 5-year OS 62%. G-CSF reduced the duration of neutropenia but did not reduce the number and severity of infectious complications. EFS of both consolidation arms was similar but length of the treatment and toxic deaths rate were reduced using blocks instead of classical consolidation. The participation in the international study increased requirements for the diagnostics and documentation and exposed the treatment results to the comparison with one of the world leading leukemia groups.

Key words:
acute myeloid leukemia, AML-BFM 98, children

Sources

1. Webb DKH, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714–1720.

2. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103: 2480–2489.

3. De Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 2004; 22: 1404–1412.

4. Grimwade D, Walker H, Oliver F, et al The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.

5. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group Study-POG 8821. Blood 1999; 94: 3707–3716.

6. Forestier E, Heim S, Blennow E, et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol 2003; 121: 566–577.

7. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 2007; 109: 4641–4647.

8. Starý J, Gajdoš P, Blažek B, et al. Sjednocení léčby dětí s akutní myeloidní leukemií v České republice podle protokolu AML-BFM 93. Čas Lék čes 2004; 143: 257–263.

9. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626–629.

10. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 460–462.

11. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 1991; 78: 325–329.

12. Zemanová Z, Michalová K, Šindelářová L, et al. Prognostic value of structural chromosomal rearrangements and small cell clones with high hyperdiploidy in children with acute lymphoblastic leukemia. Leukemia Res 2005; 29: 273–281.

13. Schwarz J, Kačírková P, Marková J, et al. Urgentní stav v hematologii: akutní promyelocytární leukemie – principy diagnostiky. Vnitř lék 2008; v tisku.

14. Trnková Z, Bedrníková R, Marková J, et al. Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia. Neoplasma 2007; 54: 383-390.

15. Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group. J Clin Oncol 2006; 24: 3686–3692.

16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649.

17. Creutzig U, Kaspers GJL. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Letter to Editor. J Clin Oncol 2004; 22: 3432–3433.

18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.

20. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Results of study AML-BFM 98 in children and adolescents with acute myeloid leukemia after a median follow-up of five years. Klin Pediatr 2008; submitted.

21. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384–4393.

22. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030–2042.

23. Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130–2138.

24. Smith FO, Alfonzo TA, Gerbing RB, et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive phase III trials by the Children’s Cancer Group: CCG 251, CCG 213, CCG 2891. Leukemia 2005; 19: 2054–2062.

25. Ravindranath Y, Chang M, Steiner CP, et al. Pediatric Oncology Group studies of acute myeloid leukemia: a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19: 2101–2116.

26. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004; 18: 72–77.

27. Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukemia trial (MRC AML 10). Br J Haematol 1999; 106: 436–444.

28. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007; 110: 3532–3539.

29. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children’s Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Blood 2008; 111: 1044–1053.

30. Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001; 80: 417–422.

31. Testi AM, Biondi A, Lo Coco F, et al. GINEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447–453.

32. Ortega J, Madero L, Martin G, et al. Treatment with all-trans-retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA group. J Clin Oncol 2005; 23: 7632–7640.

33. Rubnitz JE, Raimondi SC, Xin Tong, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 2002; 20: 2302–2309.

34. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia in neonates with Down syndrome: Children’s Oncology Group study POG 9481. Blood 2006; 107: 4606–4613.

35. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355–1360.

36. Gamis AS, Woods WG, Alfonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891. J Clin Oncol 2003; 21: 3415–3422.

37. Lehrnbecher T, Zimmermann M, Reinhardt D, et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 2007; 109: 936–943.

38. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499–4506.

39. Creutzig U, Ritter J, Zimmermann M, et al. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results in the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 1993; 11: 279–286.

40. Perel Y, Auvrignon A, Leblanc T, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial LAME 89/91. J Clin Oncol 2002; 20: 2774–2782.

Labels

Haematology Internal medicine Clinical oncology

Imatinib in the first-line treatment of chronic myelogenous leukemia in chronic phase

Apheresis red cell concentrates - evaluation of apoptosis markers in concentrates obtained from two devices

MicroRNA – small molecules with major role (not only) in hematological malignancies

DNA microchips (microarrays) in follicular lymphoma diagnostics: the pathway to „tailor-made“ therapy or to impasse?

Article was published in

Transfusion and Haematology Today

2008 Issue 4